Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.
暂无分享,去创建一个
Lothar Hennighausen | Ruth M Pfeiffer | L. Hennighausen | R. Pfeiffer | G. Robinson | W. Muller | D. Yamaji | William J Muller | Peter J Klover | Gertraud W Robinson | Daisuke Yamaji | P. Klover
[1] T. Pawson,et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.
[2] J. Kirkwood,et al. Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Bernard Roizman,et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[5] J. Casanova,et al. Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease , 2006, PLoS genetics.
[6] David E Levy,et al. STAT1 acts as a tumor promoter for leukemia development. , 2006, Cancer cell.
[7] L. Hennighausen,et al. Cre-mediated gene deletion in the mammary gland. , 1997, Nucleic acids research.
[8] H. Kantarjian,et al. First‐line therapy for chronic myeloid leukemia: Past, present, and future , 2009, American journal of hematology.
[9] Robert D. Cardiff,et al. Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.
[10] R. Schreiber,et al. Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.
[11] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[12] E. Bröcker,et al. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. , 1993, Melanoma research.
[13] G. Lesinski,et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .
[14] P. Kuo,et al. Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells. , 2007, Neoplasia.
[15] D. Levy,et al. Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.
[16] Paul J. Hertzog,et al. Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.
[17] Steven M. Holland,et al. Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation , 2001, Science.
[18] D. Tough,et al. Links between innate and adaptive immunity via type I interferon. , 2002, Current opinion in immunology.
[19] T. Eisen,et al. Immunotherapeutic strategies in kidney cancer—when TKIs are not enough , 2009, Nature Reviews Clinical Oncology.
[20] Hemant Ishwaran,et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.